TapewireFind a company

person · Reporting owner

Verratti Mark

Disclosed activity across 1 company

Tapewire entity
52469
SEC CIK
0001517026

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MYRIAD GENETICS INCMYGN · Entity 5953Chief Operating OfficerApril 14, 2026April 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MYRIAD GENETICS INC

Report date April 14, 2026 · Filed April 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect629,646 Reported balance After 2026-04-14 transaction · row 1
1 source row

Row 1 · 2026-04-14 · Tax withholding · Disposed 1,069 · Balance 629,646

F1: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 14, 2026 Filed Apr 15, 2026 20:20 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,069 $4.91 $5,248.79
Disclosure

SEC source: 0001517026-26-000008 · wk-form4_1776284439.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 629,646

F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on April 14, 2026.

Read SEC document
March 22, 2026 Filed Mar 23, 2026 20:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 2,055 $4.58 $9,411.90
Disclosure

SEC source: 0001517026-26-000006 · wk-form4_1774297376.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,715

F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

Read SEC document
March 15, 2026 Filed Mar 16, 2026 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 9,096 $4.66 $42,387.36
Disclosure

SEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 5

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 632,770

F3 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Read SEC document
March 15, 2026 Filed Mar 16, 2026 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,611 $4.66 $26,147.26
Disclosure

SEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 4

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 641,866

F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Read SEC document
March 14, 2026 Filed Mar 16, 2026 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,418 $4.66 $25,247.88
Disclosure

SEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 3

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 647,477

F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 9,164 $4.66 $42,704.24
Disclosure

SEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 652,895

F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

Read SEC document
March 12, 2026 Filed Mar 16, 2026 21:05 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 247,423 $0.00 $0.00
Disclosure

SEC source: 0001517026-26-000004 · wk-form4_1773695137.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,059

F1 · shares: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 22:30 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 32,810 $0.00 $0.00
Disclosure

SEC source: 0001517026-26-000002 · wk-form4_1770157806.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 414,636

F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

Read SEC document
September 21, 2025 Filed Sep 22, 2025 20:16 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,085 $7.77 $8,430.45
Disclosure

SEC source: 0001517026-25-000008 · wk-form4_1758572179.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,826

F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025.

Read SEC document
April 30, 2025 Filed May 1, 2025 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantPerformance-Based Restricted Stock Units · Derivative 105,785 $0.00 $0.00
Disclosure

SEC source: 0001517026-25-000005 · wk-form4_1746131228.xml · derivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,785

Underlying: Common Stock · 105,785 shares

Expires not disclosed

F1 · derivative.exercise_price: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026.

F1 · derivative.exercise_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026.

F1 · derivative.expiration_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than April 30, 2026.

Read SEC document
April 14, 2025 Filed Apr 15, 2025 20:12 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,085 $8.08 $8,766.80
Disclosure

SEC source: 0001517026-25-000002 · wk-form4_1744747947.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 382,911

F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 14, 2025.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 20:16 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,605 $9.98 $16,017.90
Disclosure

SEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 4

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 383,996

F4 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 20:16 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,096 $9.98 $10,938.08
Disclosure

SEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 3

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 385,601

F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025.

Read SEC document
March 22, 2025 Filed Mar 25, 2025 20:16 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,623 $10.01 $36,266.23
Disclosure

SEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 386,697

F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025.

Read SEC document
March 22, 2025 Filed Mar 25, 2025 20:16 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,366 $10.01 $13,673.66
Disclosure

SEC source: 0001628280-25-014724 · wk-form4_1742933792.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,320

F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025.

Read SEC document
March 15, 2025 Filed Mar 17, 2025 20:19 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,729 $10.07 $37,551.03
Disclosure

SEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 3

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 391,686

F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 20:19 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,847 $10.07 $58,879.29
Disclosure

SEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 395,415

F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:19 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 99,227 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-013145 · wk-form4_1742242769.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,262

F1 · shares: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 07, 2025 Filed Mar 5, 2025 00:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 12,758 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-010136 · wk-form4_1741134675.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,035

F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 22, 2022, subject to accomplishment of pre-determined performance metrics. On February 7, 2025, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025.

Read SEC document
October 09, 2024 Filed Oct 10, 2024 20:36 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,004 $24.37 $121,947.48
Disclosure

SEC source: 0001517026-24-000006 · wk-form4_1728592566.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,277

F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2024.

Read SEC document
October 09, 2024 Filed Oct 10, 2024 20:36 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,359 $24.37 $81,858.83
Disclosure

SEC source: 0001517026-24-000006 · wk-form4_1728592566.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,281

F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2024.

Read SEC document
September 21, 2024 Filed Sep 23, 2024 20:21 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,075 $27.64 $29,713.00
Disclosure

SEC source: 0001517026-24-000004 · wk-form4_1727122860.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,640

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 20, 2024.

Read SEC document
April 14, 2024 Filed Apr 15, 2024 20:25 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,076 $19.55 $21,035.80
Disclosure

SEC source: 0001517026-24-000002 · wk-form4_1713212713.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,715

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 12, 2024.

Read SEC document
March 24, 2024 Filed Mar 25, 2024 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,584 $22.24 $35,228.16
Disclosure

SEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 3

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,791

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024.

Read SEC document
March 24, 2024 Filed Mar 25, 2024 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,661 $22.24 $36,940.64
Disclosure

SEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,375

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024.

Read SEC document
March 22, 2024 Filed Mar 25, 2024 20:31 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,648 $22.24 $36,651.52
Disclosure

SEC source: 0001628280-24-012915 · wk-form4_1711398651.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,036

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024.

Read SEC document
March 15, 2024 Filed Mar 18, 2024 20:45 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,686 $21.16 $77,995.76
Disclosure

SEC source: 0001628280-24-011681 · wk-form4_1710794695.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,684

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 15, 2024.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 20:45 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 58,631 $0.00 $0.00
Disclosure

SEC source: 0001628280-24-011681 · wk-form4_1710794695.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 308,370

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
October 09, 2023 Filed Oct 10, 2023 20:21 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,006 $15.01 $75,140.06
Disclosure

SEC source: 0001517026-23-000009 · wk-form4_1696969253.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,739

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023.

Read SEC document
October 09, 2023 Filed Oct 10, 2023 20:21 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,360 $15.01 $50,433.60
Disclosure

SEC source: 0001517026-23-000009 · wk-form4_1696969253.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,745

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 9, 2023.

Read SEC document
September 26, 2023 Filed Sep 27, 2023 20:30 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,523 $15.99 $56,332.77
Disclosure

SEC source: 0001517026-23-000007 · wk-form4_1695846619.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,105

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2023.

Read SEC document
September 21, 2023 Filed Sep 22, 2023 20:26 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,076 $16.77 $18,044.52
Disclosure

SEC source: 0001517026-23-000005 · wk-form4_1695414390.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,628

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 21, 2023.

Read SEC document
April 14, 2023 Filed Apr 17, 2023 22:22 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 703 $22.27 $15,655.81
Disclosure

SEC source: 0001517026-23-000002 · wf-form4_168177016388393.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,704

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on April 14, 2023.

Read SEC document
March 24, 2023 Filed Mar 27, 2023 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,586 $23.72 $37,619.92
Disclosure

SEC source: 0001628280-23-009262 · wf-form4_167994886476875.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,407

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023.

Read SEC document
March 24, 2023 Filed Mar 27, 2023 20:27 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,083 $23.72 $25,688.76
Disclosure

SEC source: 0001628280-23-009262 · wf-form4_167994886476875.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,993

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023.

Read SEC document
March 22, 2023 Filed Mar 23, 2023 20:28 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,351 $22.91 $30,951.41
Disclosure

SEC source: 0001628280-23-009049 · wf-form4_167960329972877.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 266,076

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023.

Read SEC document
March 15, 2023 Filed Mar 16, 2023 20:29 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 39,405 $0.00 $0.00
Disclosure

SEC source: 0001628280-23-008316 · wf-form4_167899855540034.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,427

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
October 09, 2022 Filed Oct 11, 2022 20:35 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 5,006 $19.62 $98,217.72
Disclosure

SEC source: 0001628280-22-026252 · wf-form4_166552048411646.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,022

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022.

Read SEC document
October 09, 2022 Filed Oct 11, 2022 20:35 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,360 $19.62 $65,923.20
Disclosure

SEC source: 0001628280-22-026252 · wf-form4_166552048411646.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,028

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022.

Read SEC document
September 26, 2022 Filed Sep 27, 2022 20:32 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 2,293 $18.41 $42,214.13
Disclosure

SEC source: 0001628280-22-025565 · wf-form4_166431070757532.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,388

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022.

Read SEC document
September 25, 2022 Filed Sep 27, 2022 20:32 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 2,793 $18.69 $52,201.17
Disclosure

SEC source: 0001628280-22-025565 · wf-form4_166431070757532.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,681

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022.

Read SEC document
September 21, 2022 Filed Sep 22, 2022 20:38 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 702 $20.20 $14,180.40
Disclosure

SEC source: 0001517026-22-000009 · wf-form4_166387912215433.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,474

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 21, 2022.

Read SEC document
August 25, 2022 Filed Aug 26, 2022 20:23 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,031 $24.89 $25,661.59
Disclosure

SEC source: 0001628280-22-023770 · wf-form4_166154538405411.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,176

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022.

Read SEC document
April 14, 2022 Filed Apr 14, 2022 21:00 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001517026-22-000008 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,207

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
March 24, 2022 Filed Mar 25, 2022 21:06 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,584 $25.32 $40,106.88
Disclosure

SEC source: 0001517026-22-000006 · edgardoc.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · President, Mental Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,207

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022.

Read SEC document
March 24, 2022 Filed Mar 25, 2022 21:06 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 1,082 $25.32 $27,396.24
Disclosure

SEC source: 0001517026-22-000006 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Mental Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,791

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022.

Read SEC document
March 22, 2022 Filed Mar 23, 2022 20:52 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 19,238 $0.00 $0.00
Disclosure

SEC source: 0001517026-22-000004 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Mental Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,873

F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

Read SEC document
February 16, 2022 Filed Feb 18, 2022 22:11 UTC MYRIAD GENETICS INC MYGN · Entity 5953 GrantCommon Stock 22,616 $0.00 $0.00
Disclosure

SEC source: 0001517026-22-000002 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Mental Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,635

F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025.

Read SEC document
October 09, 2021 Filed Oct 12, 2021 20:55 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 4,991 $30.88 $154,122.08
Disclosure

SEC source: 0001517026-21-000009 · edgardoc.xml · nonDerivative · entry 2

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,019

F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021.

Read SEC document
October 09, 2021 Filed Oct 12, 2021 20:55 UTC MYRIAD GENETICS INC MYGN · Entity 5953 Tax withholdingCommon Stock 3,349 $30.88 $103,417.12
Disclosure

SEC source: 0001517026-21-000009 · edgardoc.xml · nonDerivative · entry 1

Verratti Mark · CIK 0001517026 · President, Myriad Neuroscience

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,010

F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.